These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37921907)

  • 1. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil.
    Iga K; Kiriyama A
    Clin Pharmacokinet; 2024 Jan; 63(1):43-56. PubMed ID: 37921907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.
    Varma MV; Lin J; Bi YA; Kimoto E; Rodrigues AD
    Drug Metab Dispos; 2015 Jul; 43(7):1108-18. PubMed ID: 25941268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
    Kim SJ; Toshimoto K; Yao Y; Yoshikado T; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2715-2726. PubMed ID: 28479356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges.
    Shah MB
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
    Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
    Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans.
    Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Drug Metab Dispos; 2019 Apr; 47(4):377-385. PubMed ID: 30630815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.
    Kazmi F; Barbara JE; Yerino P; Parkinson A
    Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
    Varma MV; Lai Y; Kimoto E; Goosen TC; El-Kattan AF; Kumar V
    Pharm Res; 2013 Apr; 30(4):1188-99. PubMed ID: 23307347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance.
    Miners JO; Polasek TM; Hulin JA; Rowland A; Meech R
    Pharmacol Ther; 2023 Aug; 248():108459. PubMed ID: 37263383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.
    Tornio A; Neuvonen PJ; Niemi M; Backman JT
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):83-95. PubMed ID: 27548563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
    Backman JT; Filppula AM; Niemi M; Neuvonen PJ
    Pharmacol Rev; 2016 Jan; 68(1):168-241. PubMed ID: 26721703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
    Shitara Y; Hirano M; Sato H; Sugiyama Y
    J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.
    Kim SJ; Yoshikado T; Ieiri I; Maeda K; Kimura M; Irie S; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2016 Oct; 44(10):1622-32. PubMed ID: 27457785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8.
    Takagi M; Sakamoto M; Itoh T; Fujiwara R
    Drug Metab Pharmacokinet; 2015 Aug; 30(4):288-94. PubMed ID: 26195223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
    Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
    Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.
    Yao Y; Toshimoto K; Kim SJ; Yoshikado T; Sugiyama Y
    Drug Metab Dispos; 2018 Jul; 46(7):924-933. PubMed ID: 29712725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.
    Hinton LK; Galetin A; Houston JB
    Pharm Res; 2008 May; 25(5):1063-74. PubMed ID: 17901929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay.
    Bi YA; Jordan S; King-Ahmad A; West MA; Varma MVS
    Clin Pharmacol Ther; 2024 Jun; 115(6):1336-1345. PubMed ID: 38404228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
    Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
    Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.